Recursion Pharmaceuticals Inc
NASDAQ:RXRX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.7
15.52
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RXRX stock under the Base Case scenario is 3.26 USD. Compared to the current market price of 5.7 USD, Recursion Pharmaceuticals Inc is Overvalued by 43%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Recursion Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for RXRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Recursion Pharmaceuticals Inc
Balance Sheet Decomposition
Recursion Pharmaceuticals Inc
Current Assets | 474.2m |
Cash & Short-Term Investments | 427.6m |
Receivables | 2.3m |
Other Current Assets | 44.3m |
Non-Current Assets | 252.3m |
PP&E | 159.2m |
Intangibles | 86.1m |
Other Non-Current Assets | 7m |
Current Liabilities | 108.9m |
Accounts Payable | 2.3m |
Accrued Liabilities | 48.8m |
Other Current Liabilities | 57.8m |
Non-Current Liabilities | 93.1m |
Long-Term Debt | 20.5m |
Other Non-Current Liabilities | 72.5m |
Earnings Waterfall
Recursion Pharmaceuticals Inc
Revenue
|
65.2m
USD
|
Cost of Revenue
|
-42.3m
USD
|
Gross Profit
|
22.9m
USD
|
Operating Expenses
|
-417m
USD
|
Operating Income
|
-394.2m
USD
|
Other Expenses
|
16.4m
USD
|
Net Income
|
-377.8m
USD
|
Free Cash Flow Analysis
Recursion Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Recursion Pharmaceuticals announced a merger with Exscientia, set to close by early 2025, subject to shareholder approval. The combined entity expects to save over $100 million annually, with a cash runway extending to 2027. Christopher Gibson will remain CEO, and Dave Hallett will become the Chief Scientific Officer. The merger aims to leverage complementary strengths in biology and chemistry for drug discovery and development. Key partnerships with Roche, Genentech, and Bayer were highlighted, alongside expectations of generating about $200 million in milestones over the next two years.
What is Earnings Call?
RXRX Profitability Score
Profitability Due Diligence
Recursion Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Recursion Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
RXRX Solvency Score
Solvency Due Diligence
Recursion Pharmaceuticals Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Recursion Pharmaceuticals Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RXRX Price Targets Summary
Recursion Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RXRX is 10.05 USD with a low forecast of 6.06 USD and a high forecast of 12.6 USD.
Dividends
Current shareholder yield for RXRX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
RXRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2021-04-16. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.
Contact
IPO
Employees
Officers
The intrinsic value of one RXRX stock under the Base Case scenario is 3.26 USD.
Compared to the current market price of 5.7 USD, Recursion Pharmaceuticals Inc is Overvalued by 43%.